Bay Colony Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Bay Colony Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2	Closed	–	–	596
2018 Q2	$0	Buy	+2	New	+$223	﹤0.01%	954

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CCA

Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bay Colony Advisors's LGND Position: Q3 2018 in Review

Bay Colony Advisors sold out of Ligand Pharmaceuticals (LGND) in Q3 2018, closing a stake of 2 shares.

Bay Colony Advisors first reported a position in LGND in Q2 2018 and held it in 1 quarter. The position peaked at $0 in Q2 2018. 385 funds tracked by Wall St. Rank hold LGND as of Q3 2018.

Bay Colony Advisors reported no remaining Ligand Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Bay Colony Advisors sold 2 Ligand Pharmaceuticals shares in Q3 2018.
Bay Colony Advisors first reported a position in Ligand Pharmaceuticals in Q2 2018 and held it in 1 quarter.
Bay Colony Advisors's Ligand Pharmaceuticals position peaked at $0 in Q2 2018.
385 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2018.

Based on Bay Colony Advisors's 13F filing for Q3 2018, filed 5 Nov 2018.